Amylin Pharma (AMLN) Posts Q3 GAAP Loss of $0.35; Revs Light
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Revenue Growth %: +0.7%
Financial Fact:
Interest and other expense, net: -44.71M
Today's EPS Names:
RXN, KID, CNET, More
Revenue Growth %: +0.7%
Financial Fact:
Interest and other expense, net: -44.71M
Today's EPS Names:
RXN, KID, CNET, More
Trade AMLN Now!
Amylin Pharmaceuticals (Nasdaq: AMLN) reports Q3 GAAP loss of $0.35, which may not compare to the analyst estimate of ($0.35). Revenue for the quarter was $156.1 million, which compares to the estimate of $157.65 million.
Q3 loss ex-charge of $6 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Q3 loss ex-charge of $6 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
- ChinaNet Online Holdings (CNET) Narrows Q1 Loss on Lighter Sales
- Qihoo 360 Technology (QIHU) Reports In-Line Q1 EPS; Guides Q2 Sales
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
